The Worldwide Innovative Network in personalized cancer medicine - WIN Consortium is a non profit organization initiated in 2010 under the leadership of Dr. John Mendelsohn, past president of University of Texas MD Anderson Cancer Center, Houston.
WIN Consortium is a network of 39 renowned member institutions - academic cancer centers, technology and pharmaceutical industries, cancer research non profits and patient advocates in 21 countries.
The WIN Consortium was created to achieve rapid and efficient translation of ground-breaking early diagnostic and personalized cancer medicine discoveries into the standards for clinical care, to significantly improve the outcomes and quality of life of cancer patients worldwide.
WIN Consortium and WIN Symposium are chaired by prominent oncologists such as:
- Richard L. Schilsky, Chairman, WIN Consortium, Senior Vice President & Chief Medical Officer, American Society of Clinical Oncology (ASCO)
- Josep Tabernero, Vice Chairman, WIN Consortium Head, Medical Oncology Department, Vall d’Hebron Institute of Oncology, President, European Society for Medical Oncology (ESMO)
- Razelle Kurzrock, Head of Clinical Trials Committee, WIN Consortium, Senior Deputy Center Director, Director, Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center, USA
- Brian Leyland-Jones, Chief Medical Officer, National Foundation of Cancer Research; Head of Fundraising Committee, WIN Consortium; Director The Darwin Foundation, USA
- Amir Onn, Head of Standard Operating Procedures and Repository Committee, WIN Consortium, Institute of Pulmonary Oncology, Sheba Medical Center, Israel
- Apostolia-Maria Tsimberidou, Head of Membership Committee, WIN Consortium, Professor, Department of Investigational Cancer Therapeutics, M.D. Anderson Cancer Center, University of Texas, USA
- Vladimir Lazar, Chief Scientific and Operating Officer, WIN Consortium
- Gerald Batist, Professor of Medicine and Oncology at McGill University, Director of the Segal Cancer Center, Canada
WIN was formed on the premise that we can accomplish more together than each organization can achieve working alone. WIN aims to improve cancer patients’ survival and quality of life with innovative early diagnostic and personalized cancer therapies clinical trials.
For further information on WIN's history and unique attributes, please click here.
Clinical Trials and Projects
WIN members collaboratively design and carry out global studies designed to achieve breakthroughs for patients worldwide. Our distinguished Scientific Advisory Board oversees WIN studies. For further information on our current trials, please click here.
WIN Annual Symposium
Part of WIN’s mission is also sharing information about state of the art research across the world, WIN members work, WIN trials and more generally promoting the adoption of personalized cancer medicine globally through an annual symposium.
WIN Consortium Invites You to Attend its 11th Symposium That Will Take Place on 23 - 24 June, 2019 in Paris, France
The overarching theme of the WIN Symposium 2019 is “WINnovation and Global Deployment of Precision Oncology”, which clearly maintains the Consortium’s mission. The theme will be elaborated in the following sessions:
- Transformative Innovations in Precision Oncology Trials and Challenges of Experimental Therapeutics
- Innovation in Laboratory/Preclinical Models and IT Support Platforms
- Disruptive Concepts and Innovation Across the Globe
- Deployment of Precision Oncology
- New Concepts and Therapeutics Approaches in Precision Oncology
- Best Posters’ Award
Reasons for Joining Us
- Listen to 30 Precision Oncology leaders from academia, industry and research organizations.
- View over 70 thought provoking abstracts from like-minded professionals
- Showcase your work
- Engage in the open discussions and network with other professionals in oncology
To view the past WIN Symposia, including the meeting report and speaker presentations, please click here.